The NCCN guidelines recommend plasma genotyping in the event that sufficient tissue is not available, both at initial diagnosis as well as at disease progression.3 However, the application of ctDNA for detecting EGFR mutations at initial diagnosis in patients without pathologic confirmation of lung cancer has not been well established. Here, EGFR is linked to lung cancer.